- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03697304
Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 (Ezabenlimab) Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors.
How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups.
Each group receives BI 754091 in combination with another medicine.
The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute (University of Alberta)
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1Z6
- Princess Margaret Cancer Centre
-
-
-
-
-
Glasgow, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Centre
-
London, United Kingdom, SE1 9RT
- Guy's Hospital
-
London, United Kingdom, W1G 6AD
- Sarah Cannon Research Institute
-
London, United Kingdom, NW1 2BU
- University College Hospital
-
-
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists
-
Saint Petersburg, Florida, United States, 33705
- Florida Cancer Specialists
-
Tallahassee, Florida, United States, 32308
- Florida Cancer Specialists
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists - East
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma University School of Community Medicine
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Tennessee Oncology
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College Of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
Master Protocol:
- Provision of signed and dated, written Master informed consent form (ICF) prior to any trial-specific procedures, sampling, or analyses.
- Patient ≥18 years of age at the time of signature of the ICF.
- Eastern Cooperative Oncology Group (ECOG) score: 0 or 1.
- Patient must agree to a pre-treatment biopsy (if archival tissue is not available) and on-treatment tumour biopsy.
- Life expectancy of at least 12 weeks after the start of the treatment according to the Investigator's judgement.
- Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be willing and able to use highly effective methods of birth control (that result in a low failure rate of less than 1% per year when used consistently and correctly) during trial participation and for at least 6 months after the last administration of trial medication.
Module A:
- Histologically confirmed diagnosis of one of the following cohorts:
- Cohort 1 GEC - Locally advanced, unresectable or metastatic gastric adenocarcinoma or gastro oesophageal adenocarcinoma (GEC) (defined as primary tumour localisation below the gastro oesophageal junction (GEJ) with prior anti-PD-1 or anti-PD-L1 based treated tumour.
- Cohort 2 Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based therapy: Any advanced or metastatic solid tumour with previously anti-PD-1 or anti-PD-L1 based treatment who progressed after achieving benefit
- Cohort 3 Patients with primary resistance to anti-PD-1 or anti-PD-L1 based therapy: Select advanced or metastatic solid tumour types with previous anti-PD- 1/PD-L1 based treated tumour without achieving benefit.
- All patients must have measurable lesions according to RECIST v1.1
- Patient must agree to pre- and on-treatment tumour biopsies. If archived tumour tissue is available from the last treatment failure, sections may be supplied instead of a pre-treatment biopsy.
Module C:
Histologically confirmed diagnosis of one of the following cohorts:
- Cohort 1: GEC: Locally advanced, unresectable or metastatic gastric adenocarcinoma or GEC.
- Cohort 2: Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based therapy: Any advanced or metastatic solid tumour (excluding NSCLC and melanoma) with previously anti-PD-1 or anti-PD-L1 based treatment which progressed after achieving benefit.
- Cohort 3: Patients with primary resistance to anti-PD-1 or anti-PD-L1 based therapy: Select advanced or metastatic solid tumour types with previous anti-PD-1/PD-L1 based treated tumour without achieving benefit.
- Cohort 4: Locally advanced, unresectable or metastatic second line or greater, microsatellite stable (MSS) colorectal cancer.
- Cohort 5: Advanced Endometrial cancer: Endometrial carcinoma that is pMMR (Mismatch Repair-Proficient)/MSS and is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy.
- All patients must have at least one measurable lesion according to RECIST v1.1
- Further inclusion criteria apply
Exclusion Criteria
Master Protocol:
- Any investigational treatment anti-tumour treatment within 4 weeks or within 5 half-life periods (whichever is shorter) prior to the initiation of trial treatment.
- More than one anti-PD-(L)1-based treatment regimen prior to entering study
- Major surgery ('major' according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g., hip replacement.
- Known history of severe hypersensitivity reactions to other mAbs or known hypersensitivity to the trial drugs or their excipients.
- Presence of central nervous system (CNS) metastases, unless treated and asymptomatic and off corticosteroids and/or anticonvulsant therapy for at least 2 weeks prior to start of treatment.
- Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study treatment.
- Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy. Patients who were permanently discontinued from previous anti-PD-1 or anti-PD-L1 therapy because of a immune-related adverse event (irAE).
Module A:
- Previous treatment with an anti-LAG-3 Agent
Module C:
- Unresolved, Grade >1 toxicity before the start of treatment with the study drug except for hair loss (alopecia) and hypothyroidism that requires thyroid hormone supplements but is asymptomatic under therapy.
- Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > New York Heart Association [NYHA] II)
- History of severe haemorrhagic or thromboembolic event in the past 12 months
- Known inherited predisposition to bleeding or to thrombosis, in the opinion of the investigator - Further exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 - Module A
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 2 - Module A
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 3 - Module A
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 1 - Module C
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 2 - Module C
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 3 - Module C
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 4 - Module C
|
Solution for infusion
Other Names:
Solution for infusion
|
Experimental: Cohort 5 - Module C
|
Solution for infusion
Other Names:
Solution for infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint of the trial is objective response (OR), defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator
Time Frame: Up to 32 months
|
Up to 32 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response (DoR), defined as the time from first documented CR or PR (RECIST v1.1) until the earlier of disease progression or death among patients with OR
Time Frame: Up to 32 months
|
Up to 32 months
|
Disease control (DC), defined as best overall response of CR, PR, or stable disease (SD) according to RECIST v1.1 as assessed by the Investigator
Time Frame: Up to 32 months
|
Up to 32 months
|
Progression-free survival (PFS), defined as the time from first treatment until PD or death from any cause, whichever occurs earlier
Time Frame: Up to 32 months
|
Up to 32 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1381-0009
- 2018-002344-81 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Metastasis
-
Betta Pharmaceuticals Co., Ltd.Recruiting
-
BayerCompleted
-
BayerCompletedNeoplasm Metastasis / Bone and BonesBelgium, Spain, Taiwan, United States, Japan, Russian Federation, Canada, Finland, Korea, Republic of, Singapore, Australia, Germany, Israel, United Kingdom, Italy, France, Poland, Brazil, Czechia, Norway, Sweden, Hong Kong
-
National Cancer Institute (NCI)TerminatedCancer | Neoplasm Metastasis | Metastasis | Neoplasm | Radiation OncologyUnited States
-
MedtronicNeuroCompletedMetastasis Spine | Metastasis to BoneUnited States, Luxembourg, Germany, France, Canada
-
Cho Ray HospitalUniversity of Medicine and Pharmacy at Ho Chi Minh CityRecruitingSynchronous Neoplasm | Liver Metastasis Colon CancerVietnam
-
Li MinRecruiting
-
Da FuGanzhou City People's HospitalRecruiting
-
University of Mississippi Medical CenterCompletedMetastasisUnited States
-
Assiut UniversityNot yet recruiting
Clinical Trials on BI 754091
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimWithdrawnAnal Canal Squamous Cell CarcinomaKorea, Republic of
-
Boehringer IngelheimCompletedNeoplasms | Carcinoma, Non-Small-Cell LungUnited States, Spain, United Kingdom, Canada, Poland
-
Boehringer IngelheimTerminatedNeoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm MetastasisUnited States
-
Boehringer IngelheimRecruitingSolid TumorsSpain, Japan, United Kingdom, United States
-
Boehringer IngelheimCompletedNeoplasmsSpain, United States, United Kingdom
-
Boehringer IngelheimCompletedNeoplasmsUnited States, Canada, United Kingdom
-
Boehringer IngelheimRecruitingHead and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver CancerJapan
-
Boehringer IngelheimActive, not recruitingNeoplasms | Non-squamous, Non-Small-Cell Lung CancerUnited States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
-
Boehringer IngelheimCompleted